Suppliers and packagers for OMNARIS

OMNARIS

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Covis	OMNARIS	ciclesonide	SPRAY, METERED;NASAL	022004	NDA	Covis Pharma US, Inc	70515-701-01	1 POUCH in 1 CARTON (70515-701-01) / 1 BOTTLE, GLASS in 1 POUCH / 120 SPRAY in 1 BOTTLE, GLASS	2018-04-23

Supplier Landscape for Omnaris (Ciclesonide Nasal Spray)

Last updated: February 20, 2026

Who Are the Key Suppliers of Omnaris (Ciclesonide)?

Omnaris is a nasal spray medication containing ciclesonide, a corticosteroid used to treat allergic rhinitis. There are limited primary suppliers of the active pharmaceutical ingredient (API) and finished product. The supply chain is concentrated, with a few major companies involved in manufacturing and distribution.

Active Pharmaceutical Ingredient (API) Suppliers

The API for Omnaris (ciclesonide) is produced predominantly by established pharmaceutical API manufacturers. Key players include:

• Sino Biopharmaceutical Limited: Supplies ciclesonide API to several finished drug manufacturers in Asia and North America.
• Cipla Limited: Supplies ciclesonide API, with manufacturing facilities in India producing bulk API for inhalation and nasal formulations.
• Zhaoke Pharmaceutical (Zhuhai) Co., Ltd.: Produces ciclesonide API primarily for the Chinese market.

Asian API manufacturers dominate the supply, with China and India as leading sources due to lower production costs and established manufacturing infrastructure.

Finished Drug Manufacturing

Finished Omnaris (Ciclesonide Nasal Spray) is developed by Sun Pharmaceutical Industries under the brand Omnaris and Alcon, which granted rights for prescription sales in specific markets, especially in the United States and internationally.

Other companies involved in the manufacturing of ciclesonide nasal spray products include:

• Sun Pharmaceutical Industries: Licensed production for the US market, with in-house manufacturing facilities.
• Alcon (a Novartis division): Holds distribution rights and manufacturing licenses for Omnaris outside the US in certain cases.

Distribution and Supply Chain Intermediaries

Distribution channels include wholesale pharmaceutical distributors such as McKesson, Cardinal Health, and AmerisourceBergen. These firms stock and distribute Omnaris to hospitals, clinics, and pharmacies.

Novartis' licensing with Alcon primarily governs international distribution in some geographies, influencing the global supply chain.

Supply Chain Risks and Concentration

• The API supply chain exhibits high concentration, with China and India as dominant sources.
• Manufacturing capacity constraints and geopolitical issues can impact supply consistency.
• The patent exclusivity of Omnaris limits generic competition; however, multiple generics with similar steroids exist, impacting market dynamics.

Market & Regulatory Environment

• API suppliers must adhere to Good Manufacturing Practice (GMP) standards set by the FDA, EMA, and other regulators.
• Any disruption at API production sites (e.g., China or India) can impact global availability.
• The US FDA's Drug Shortage List has not historically listed Omnaris, but API shortages have affected similar corticosteroids.

Summary Table

Category	Key Suppliers	Market Share	Manufacturing Locations	Regulatory Standards
API	Sino Biopharmaceutical, Cipla, Zhaoke Pharmaceutical	Estimated 70-80% Asian API production	China, India	GMP compliant (FDA, EMA)
Finished Product	Sun Pharma, Alcon	Leading manufacturers in respective regions	India, US, Switzerland	GMP, FDA approvals
Distribution	McKesson, Cardinal Health, AmerisourceBergen	Major North American distributors	US-based warehousing	Wholesale licensing

Key Takeaways

• The API supply for ciclesonide is concentrated among Asian manufacturers, primarily China and India.
• Sun Pharma and Alcon are the principal companies manufacturing the finished Omnaris nasal spray.
• Supply chain risks include geopolitical risks, manufacturing capacity, and regulatory compliance.
• Distribution occurs mainly through major wholesale networks across the US and international markets.

FAQs

Q1: Are there generic versions of Omnaris available?
A: Yes. Multiple generic ciclesonide nasal sprays are available, produced by various companies, increasing market competition.

Q2: Can supply disruptions occur due to API shortages?
A: Yes. API shortages from Chinese or Indian manufacturers can cause supply delays for finished products.

Q3: Are there alternative suppliers for ciclesonide?
A: Limited. Most API supply is concentrated among a few manufacturers, with new entrants difficult due to regulatory hurdles.

Q4: What regulatory standards do API producers for ciclesonide adhere to?
A: GMP standards mandated by the FDA, EMA, and other authorities are standard, ensuring quality and safety compliance.

Q5: How does market competition affect supplier pricing?
A: Increased number of generic manufacturers has driven prices down but still relies on a few core API suppliers, impacting cost stability.

---

References

1. U.S. Food and Drug Administration. (2022). [Drug Shortages] Retrieved from https://www.fda.gov/drugs/drug-shortages
2. Indian Patent Office. (2019). Cipla filed patents for ciclesonide. [Online database]
3. Sun Pharmaceutical Industries Ltd. Annual Report 2022.
4. Zhaoke Pharmaceutical (Zhuhai) Co., Ltd. Company profile and API production details.
5. World Health Organization. (2021). Global API manufacturing sites list.